Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bay State Times.
Press releases published on June 4, 2025
Elicio Therapeutics Secures $10 Million in Financing
GlobeNewswire
·
June 4, 2025
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage …
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
GlobeNewswire
·
June 4, 2025
CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society …
617 Boston Movers Announce Launch of 24 Hour Relocation Services in Boston, MA
GlobeNewswire
·
June 4, 2025
Boston, MA, June 04, 2025 (GLOBE NEWSWIRE) -- 617 Boston Movers, a top-rated Boston moving company, is happy to announce the launch of its 24-hour moving services. Catering to both commercial and residential customers, the trained team of local personnel …
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 4, 2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET. The …
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
GlobeNewswire
·
June 4, 2025
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of- …
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
GlobeNewswire
·
June 4, 2025
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising interest from patients and payers for an off-ramp from …
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
GlobeNewswire
·
June 4, 2025
WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on …
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 4, 2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, …